Invivyd, Inc. announced that Jeremy Gowler, the Interim Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer of Invivyd, Inc, ceased serving as an executive officer and as the Company?s ?principal executive officer,? effective as of May 30, 2024, with his employment terminating on June 29, 2024. The Board of Directors of the Company is continuing its search for a permanent Chief Executive Officer.

Effective May 30, 2024, William Duke, Jr., the Company?s Chief Financial Officer, will serve as the Company?s ?principal executive officer?. Mr. Duke will continue to serve as ?principal financial officer? and ?principal accounting officer?

of the Company. Mr. Duke, 51, has served as the Company?s Chief Financial Officer since September 2023. He brings more than 25 years of finance, accounting, and operations experience, including over a decade of senior leadership experience in the biotechnology industry.

Prior to joining the Company, Mr. Duke served as the Chief Financial Officer of Apexigen, Inc. from June 2022 to August 2023 where he was responsible for all areas of finance and accounting and helped guide the company through its sale to Pyxis Oncology, Inc. Before Apexigen, Mr. Duke was Chief Financial Officer of Kaleido Biosciences, Inc. from November 2019 to April 2022, where he led the successful completion of multiple financings. Prior to Kaleido Biosciences, he was Chief Financial Officer of Pulmatrix, Inc. from June 2015 to November 2019, where he helped negotiate the company?s first product partnership and led the successful completion of several public offerings. Prior to that, he held senior financial leadership roles at Valeritas, Inc. and Genzyme Corporation, where he helped in the sale of the company to Sanofi.

Mr. Duke is a certified public accountant and holds a B.S. in Business Administration from Stonehill College and an M.B.A. from Bentley College.